

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC

CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

**FINANCIAL INFORMATION OF
CSPC INNOVATION PHARMACEUTICAL CO., LTD.
FOR THE YEAR ENDED 31 DECEMBER 2024**

In compliance with the relevant requirements of Shenzhen Stock Exchange, CSPC Innovation Pharmaceutical Co., Ltd. (“**CSPC Innovation**”), a subsidiary of CSPC Pharmaceutical Group Limited (the “**Company**”) listed on the ChiNext of Shenzhen Stock Exchange (Stock Code: 300765), has on 20 March 2025 published its annual report for the year ended 31 December 2024 (the “**2024 Annual Report**”) on the information disclosure webpage of Shenzhen Stock Exchange’s website at <http://www.szse.cn/disclosure/listed/notice/index.html>. CSPC Innovation’s financial information was prepared in accordance with the China Accounting Standards for Business Enterprises.

Set out in the appendices to this announcement (the “**Appendices**”) is the principal financial data of CSPC Innovation extracted from the 2024 Annual Report prepared in Chinese. In case of any inconsistency between the Chinese version and the English version, the Chinese version shall prevail.

Shareholders and potential investors of the Company are reminded that the financial information of CSPC Innovation in the 2024 Annual Report and in the Appendices are consolidated financial information of CSPC Innovation for the year ended 31 December 2024, rather than that of the Company. They should exercise caution when dealing in the securities of the Company.

By Order of the Board
CSPC Pharmaceutical Group Limited
CAI Dongchen
Chairman

Hong Kong, 20 March 2025

As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin and Mr. CHEN Weiping as executive directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as independent non-executive directors.

APPENDIX I

KEY ACCOUNTING INFORMATION AND FINANCIAL INDICATORS

Currency: RMB

	2024	2023		Increase/decrease of the year compared with the last year	2022	
		Before adjustments	After adjustments		After adjustments	Before adjustments
Revenue (Yuan)	1,980,753,001.94	2,501,699,905.93	2,538,713,472.31	-21.98%	2,626,488,832.63	2,838,103,333.96
Net profit attributable to shareholders of the listed company (Yuan)	53,726,318.63	755,557,253.28	434,435,597.81	-87.63%	726,277,891.97	503,021,231.16
Net profit attributable to shareholders of the listed company after deducting non-recurring profit or loss (Yuan)	42,341,882.94	743,672,985.61	743,672,985.61	-94.31%	657,608,747.31	657,608,747.31
Net cash flow generated from operating activities (Yuan)	-1,235,054,404.22	927,241,226.87	721,139,552.49	-271.26%	640,717,518.79	757,890,334.52
Basic earnings per share (Yuan/share)	0.0384	0.6533	0.3110	-87.65%	1.1734	0.8127
Diluted earnings per share (Yuan/share)	0.0384	0.6533	0.3110	-87.65%	1.1734	0.8127
Weighted average return on net assets	1.10%	16.23%	9.36%	-8.26%	20.11%	13.93%
	End of 2024	End of 2023		Increase/decrease compared with the end of the last year	End of 2022	
		Before adjustments	After adjustments		After adjustments	Before adjustments
Total assets (Yuan)	6,022,115,755.32	5,632,123,851.51	7,472,208,452.03	-19.41%	4,584,035,512.38	5,604,815,058.35
Net assets attributable to shareholders of the listed company (Yuan)	3,730,544,275.59	5,078,808,635.08	5,280,823,722.20	-29.36%	3,935,600,634.14	4,123,184,275.50

APPENDIX II

NON-RECURRING PROFIT OR LOSS ITEMS AND AMOUNTS

Unit: Yuan Currency: RMB

Items	Amounts for 2024	Amounts for 2023	Amounts for 2022
Gains/losses on disposal of non-current assets (including the portion offset with the provision for impairment of assets)	545,287.31	-1,819,411.71	-4,562,657.58
Government grants recognised in profit or loss for the current period (excluding those closely related to the company's normal business operations, complied with national policies, granted according to established standards, and continuously affecting the company's profit or loss)	15,980,013.00	13,821,721.77	4,865,650.37
Profit or loss from changes in fair value of financial assets and financial liabilities and profit or loss from disposal of financial assets and financial liabilities held by non-financial enterprises, other than effective hedging activities related to normal business operations of the company	1,733,768.57		
Profit or loss from entrusted investments or assets management			6,517,950.19
Net profit or loss of subsidiaries from the beginning of the current period to the date of consolidation arising from business combination under common control		-629,650,304.85	-374,556,902.25
Non-operating income and expenses other than the items above	-2,988,904.19	2,143,922.54	59,880.88
Less: Impact of income tax	376,600.30	2,352,729.90	1,413,003.18
Impact of minority interests (after tax)	3,509,128.70	-308,619,414.35	-214,501,565.42
Total	11,384,435.69	-309,237,387.80	-154,587,516.15

APPENDIX III

SIGNIFICANT CHANGES IN ASSETS COMPONENTS

Unit: Yuan Currency: RMB

	End of 2024		Beginning of 2024		Changes	Descriptions of significant changes
	Amounts	Proportion to total assets	Amounts	Proportion to total assets		
Cash and bank balances	872,081,872.91	14.48%	3,770,190,307.96	50.46%	-35.98%	Mainly due to purchase of large-amount time deposits, repurchase of shares, and distribution of cash dividends of the company, as well as settlement of R&D expenses by Megalith Biopharma.
Trade receivables	314,097,126.88	5.22%	392,376,024.64	5.25%	-0.03%	No significant change
Contract assets		0.00%	11,874,999.98	0.16%	-0.16%	Contracted R&D projects have been completed.
Inventories	398,668,570.98	6.62%	224,821,141.86	3.01%	3.61%	Mainly due to launch of new products by Megalith and increase in overseas inventory of caffeine during the reporting period.
Investment properties		0.00%		0.00%	0.00%	No significant change
Long-term equity investments	264,448,153.62	4.39%	267,068,968.17	3.57%	0.82%	No significant change
Fixed assets	2,046,598,550.77	33.98%	2,081,907,931.60	27.86%	6.12%	No significant change
Construction in progress	620,225,532.01	10.30%	228,712,565.18	3.06%	7.24%	Mainly due to the construction of new plants and office building of Megalith Biopharma, and the construction of health supplement products and special medical food production projects.
Right-of-use assets	1,328,072.18	0.02%	1,612,974.52	0.02%	0.00%	No significant change
Short-term borrowings		0.00%		0.00%	0.00%	No significant change
Contract liabilities	18,683,904.44	0.31%	19,803,395.73	0.27%	0.04%	No significant change
Long-term borrowings		0.00%		0.00%	0.00%	No significant change
Lease liabilities		0.00%	841,216.40	0.01%	-0.01%	No significant change